| Year |
Citation |
Score |
| 2024 |
Pokhrel NK, Panfil A, Habib H, Seeniraj S, Joseph A, Rauch D, Cox L, Sprung R, Gilmore PE, Zhang Q, Townsend RR, Yu L, Yilmaz AS, Aurora R, Park W, ... ... Weilbaecher KN, et al. HTLV-1 infected T cells cause bone loss via small extracellular vesicles. Biorxiv : the Preprint Server For Biology. PMID 38496506 DOI: 10.1101/2024.02.29.582779 |
0.338 |
|
| 2023 |
Faget DV, Luo X, Inkman MJ, Ren Q, Su X, Ding K, Waters MR, Raut GK, Pandey G, Dodhiawala PB, Ramalho-Oliveira R, Ye J, Cole T, Murali B, Zheleznyak A, ... ... Weilbaecher KN, et al. p38MAPKa stromal reprogramming sensitizes metastatic breast cancer to immunotherapy. Cancer Discovery. PMID 36883955 DOI: 10.1158/2159-8290.CD-22-0907 |
0.308 |
|
| 2022 |
Greaney SK, Amin N, Prudner BC, Compernolle M, Sandell LJ, Tebb SC, Weilbaecher KN, Abeln P, Luo J, Tao Y, Hirbe AC, Peterson LL. Yoga Therapy During Chemotherapy for Early-Stage and Locally Advanced Breast Cancer. Integrative Cancer Therapies. 21: 15347354221137285. PMID 36412916 DOI: 10.1177/15347354221137285 |
0.576 |
|
| 2021 |
Glaser DE, Curtis MB, Sariano PA, Rollins ZA, Shergill BS, Anand A, Deely AM, Shirure VS, Anderson L, Lowen JM, Ng NR, Weilbaecher K, Link DC, George SC. Organ-on-a-chip model of vascularized human bone marrow niches. Biomaterials. 121245. PMID 34810038 DOI: 10.1016/j.biomaterials.2021.121245 |
0.412 |
|
| 2021 |
McKee AM, Kirkup BM, Madgwick M, Fowler WJ, Price CA, Dreger SA, Ansorge R, Makin KA, Caim S, Le Gall G, Paveley J, Leclaire C, Dalby M, Alcon-Giner C, Andrusaite A, ... ... Weilbaecher KN, et al. Antibiotic-induced disturbances of the gut microbiota result in accelerated breast tumor growth. Iscience. 24: 103012. PMID 34522855 DOI: 10.1016/j.isci.2021.103012 |
0.328 |
|
| 2021 |
Su X, Xu Y, Fox GC, Xiang J, Kwakwa KA, Davis JL, Belle JI, Lee WC, Wong WH, Fontana F, Hernandez-Aya L, Kobayashi T, Tomasson HM, Su J, Bakewell SJ, ... ... Weilbaecher KN, et al. Breast cancer derived GM-CSF regulates arginase 1 in myeloid cells to promote an immunosuppressive microenvironment. The Journal of Clinical Investigation. PMID 34520398 DOI: 10.1172/JCI145296 |
0.331 |
|
| 2021 |
Hartkopf AD, Brucker SY, Taran FA, Harbeck N, von Au A, Naume B, Pierga JY, Hoffmann O, Beckmann MW, Rydén L, Fehm T, Aft R, Solà M, Walter V, Rack B, ... ... Weilbaecher K, et al. Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. European Journal of Cancer (Oxford, England : 1990). 154: 128-137. PMID 34265505 DOI: 10.1016/j.ejca.2021.06.028 |
0.347 |
|
| 2021 |
Fontana F, Xiang J, Su X, Tycksen E, Nassau R, Fox G, Leanza G, Weilbaecher K, Civitelli R. N-cadherin in osteolineage cells modulates stromal support of tumor growth. Journal of Bone Oncology. 28: 100356. PMID 33912383 DOI: 10.1016/j.jbo.2021.100356 |
0.416 |
|
| 2021 |
Fox GC, Su X, Davis JL, Xu Y, Kwakwa KA, Ross MH, Fontana F, Xiang J, Esser AK, Cordell E, Pagliai K, Dang HX, Sivapackiam J, Stewart SA, Maher CA, ... ... Weilbaecher KN, et al. Targeted therapy to β3 integrin reduces chemoresistance in breast cancer bone metastases. Molecular Cancer Therapeutics. PMID 33785647 DOI: 10.1158/1535-7163.MCT-20-0931 |
0.457 |
|
| 2020 |
Lanigan LG, Hildreth BE, Dirksen WP, Simmons JK, Martin CK, Werbeck JL, Thudi NK, Papenfuss TL, Boyaka PN, Toribio RE, Ward JM, Weilbaecher KN, Rosol TJ. In vivo tumorigenesis, osteolytic sarcomas, and tumorigenic cell lines from transgenic mice expressing the human T-lymphotropic virus type 1 (HTLV-1) Tax viral oncogene. The American Journal of Pathology. PMID 33181139 DOI: 10.1016/j.ajpath.2020.10.014 |
0.416 |
|
| 2020 |
Ademuyiwa FO, Rimawi MF, Summa T, Luo J, Wang T, Suresh R, Peterson L, Naughton M, Frith A, Hernandez-Aya L, Weilbaecher K, Ma C, Chaudhuri AA, Feng Y, Skidmore ZL, et al. Abstract P2-16-03: Neoadjuvant treatment of triple negative breast cancer patients with docetaxel and carboplatin to assess anti-tumor activity Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P2-16-03 |
0.387 |
|
| 2019 |
Kohart NA, Elshafae SM, Supsahvad W, Alasonyalilar-Demirer A, Panfil AR, Xiang J, Dirksen WP, Veis DJ, Green PL, Weilbaecher KN, Rosol TJ. Mouse model recapitulates the phenotypic heterogeneity of human adult T-cell leukemia/lymphoma in bone. Journal of Bone Oncology. 19: 100257. PMID 31871882 DOI: 10.1016/J.Jbo.2019.100257 |
0.506 |
|
| 2019 |
Kohart NA, Elshafae SM, Demirer AA, Dirksen WP, Breitbach JT, Shu ST, Xiang J, Weilbaecher KN, Rosol TJ. Parathyroid hormone-related protein promotes bone loss in T-cell leukemia as well as in solid tumors. Leukemia & Lymphoma. 1-11. PMID 31592701 DOI: 10.1080/10428194.2019.1672055 |
0.427 |
|
| 2019 |
Xiang J, Rauch DA, Huey DD, Panfil AR, Cheng X, Esser AK, Su X, Harding JC, Xu Y, Fox GC, Fontana F, Kobayashi T, Su J, Sundaramoorthi H, Wong WH, ... ... Weilbaecher KN, et al. HTLV-1 viral oncogene HBZ drives bone destruction in adult T cell leukemia. Jci Insight. 4. PMID 31578308 DOI: 10.1172/Jci.Insight.128713 |
0.442 |
|
| 2019 |
Chen I, Guo F, Summa T, Luo J, Ellis M, Ma C, Weilbaecher K, Naughton M, Suresh R, Peterson L, Cherian M, Bose R, Frith A, Hernandez-Aya L, Gillanders W, et al. Abstract P1-15-05: Is absolute lymphocyte count associated with platinum-sensitivity? A phase II single arm study evaluating the efficacy of neoadjuvant carboplatin and docetaxel in triple negative breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P1-15-05 |
0.332 |
|
| 2018 |
Cortes Castan J, Martín M, Pernas Simon S, Gomez Pardo P, Lopez-Tarruella S, Gil Martin M, Manso LM, Ciruelos EM, Perez Fidalgo JA, Hernando C, Ademuyiwa F, Weilbaecher K, Mayer IA, Pluard T, Martinez Garcia M, et al. Balixafortide (a novel CXCR4 inhibitor) and eribulin in HER2-neg metastatic breast cancer (MBC) patients (pts): A phase I trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii91-viii92. PMID 32138119 DOI: 10.1093/Annonc/Mdy272.277 |
0.31 |
|
| 2018 |
Toriola AT, Appleton CM, Zong X, Luo J, Weilbaecher K, Tamimi RM, Colditz GA. Circulating Receptor Activator of Nuclear Factor-κB (RANK), RANK ligand (RANKL) and Mammographic Density in Premenopausal Women. Cancer Prevention Research (Philadelphia, Pa.). PMID 30352839 DOI: 10.1158/1940-6207.Capr-18-0199 |
0.317 |
|
| 2018 |
Murali B, Ren Q, Luo X, Faget DV, Wang C, Johnson RM, Gruosso T, Flanagan KC, Fu Y, Leahy KM, Alspach E, Su X, Ross MH, Burnette B, Weilbaecher KN, et al. Inhibition of the stromal p38MAPK/MK2 pathway limits breast cancer metastases and chemotherapy-induced bone loss. Cancer Research. PMID 30093561 DOI: 10.1158/0008-5472.Can-18-0234 |
0.508 |
|
| 2018 |
Pernas S, Martin M, Kaufman PA, Gil-Martin M, Gomez Pardo P, Lopez-Tarruella S, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, Ademuyiwa FO, Weilbaecher K, Mayer I, Pluard TJ, Martinez Garcia M, et al. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. The Lancet. Oncology. PMID 29706375 DOI: 10.1016/S1470-2045(18)30147-5 |
0.348 |
|
| 2018 |
Meyer MA, Baer JM, Knolhoff BL, Nywening TM, Panni RZ, Su X, Weilbaecher KN, Hawkins WG, Ma C, Fields RC, Linehan DC, Challen GA, Faccio R, Aft RL, DeNardo DG. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Nature Communications. 9: 1250. PMID 29593283 DOI: 10.1038/s41467-018-03600-6 |
0.353 |
|
| 2018 |
Kotagiri N, Cooper ML, Rettig M, Egbulefu C, Prior J, Cui G, Karmakar P, Zhou M, Yang X, Sudlow G, Marsala L, Chanswangphuwana C, Lu L, Habimana-Griffin L, Shokeen M, ... ... Weilbaecher K, et al. Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancer. Nature Communications. 9: 275. PMID 29348537 DOI: 10.1038/S41467-017-02758-9 |
0.388 |
|
| 2018 |
Ademuyiwa F, Feng Y, Skidmore Z, Kunisaki J, Walker J, Fulton R, Krysiak K, Skinner T, Weilbaecher K, Ma C, Griffith O, Griffith M. Abstract P2-02-14: Circulating tumor DNA predicts clinical outcome in early stage triple negative breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P2-02-14 |
0.342 |
|
| 2018 |
Kaufman PA, Pernas S, Martin M, Gil-Martin M, Pardo PG, Sara LT, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, Ademuyiwa FO, Weilbaecher K, Mayer I, Pluard TJ, Garcia MM, et al. Balixafortide (a CXCR4 antagonist) plus eribulin in HER2-negative metastatic breast cancer (MBC): A Phase I open-label trial European Journal of Cancer. 92. DOI: 10.1016/S0959-8049(18)30575-6 |
0.304 |
|
| 2017 |
Esser AK, Rauch DA, Xiang J, Harding JC, Kohart NA, Ross MH, Su X, Wu K, Huey D, Xu Y, Vij K, Green PL, Rosol TJ, Niewiesk S, Ratner L, ... Weilbaecher KN, et al. HTLV-1 viral oncogene HBZ induces osteolytic bone disease in transgenic mice. Oncotarget. 8: 69250-69263. PMID 29050201 DOI: 10.18632/Oncotarget.20565 |
0.518 |
|
| 2017 |
Ross MH, Esser AK, Fox GC, Schmieder AH, Yang X, Hu G, Pan D, Su X, Xu Y, Novack DV, Walsh T, Colditz GA, Lukaszewicz GH, Cordell E, Novack JS, ... ... Weilbaecher KN, et al. Bone-induced expression of integrin β3 enables targeted nanotherapy of breast cancer metastases. Cancer Research. PMID 28855208 DOI: 10.1158/0008-5472.Can-17-1225 |
0.489 |
|
| 2017 |
Ademuyiwa F, Miller C, Li T, Sanati S, Ma C, Weilbaecher K, Ellis M, Mardis E. Abstract P1-07-11: Tumor genomic profiling of triple negative breast cancer during neoadjuvant chemotherapy: Results from a prospective trial of carboplatin and docetaxel Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P1-07-11 |
0.373 |
|
| 2016 |
D'Amico L, Mahajan S, Capietto AH, Yang Z, Zamani A, Ricci B, Bumpass DB, Meyer M, Su X, Wang-Gillam A, Weilbaecher K, Stewart SA, DeNardo DG, Faccio R. Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer. The Journal of Experimental Medicine. PMID 27045006 DOI: 10.1084/Jem.20150950 |
0.447 |
|
| 2016 |
Fontana F, Ge X, Su X, Xiang J, Cenci S, Civitelli R, Shoghi K, Akers W, Shokeen M, Weilbaecher K. Acetate metabolism in Multiple Myeloma identifies 11 C-Acetate PET as a novel strategy to image bone disease and response to treatment in preclinical models Bone Abstracts. DOI: 10.1530/Boneabs.5.P122 |
0.369 |
|
| 2016 |
Ademuyiwa FO, Li S, Luo J, Skinner T, Hoshower J, Ma CX, Weilbaecher K, Naughton M, Hernandez-Aya L, Mardis ER, Ellis MJ. Abstract CT091: A neoadjuvant co-clinical trial in triple-negative breast cancer patients with genomic discovery analysis Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct091 |
0.36 |
|
| 2016 |
Esser A, Rauch D, Xiang J, Harding J, Kohart N, Green P, Niewiesk S, Rosol T, Ratner L, Weilbaecher K. Abstract 3285: HTLV-1 viral oncogene Hbz induces leukemia with osteolytic bone involvement in mice Cancer Research. 76: 3285-3285. DOI: 10.1158/1538-7445.Am2016-3285 |
0.606 |
|
| 2015 |
Luo X, Fu Y, Loza AJ, Murali B, Leahy KM, Ruhland MK, Gang M, Su X, Zamani A, Shi Y, Lavine KJ, Ornitz DM, Weilbaecher KN, Long F, Novack DV, et al. Stromal-Initiated Changes in the Bone Promote Metastatic Niche Development. Cell Reports. PMID 26725121 DOI: 10.1016/J.Celrep.2015.12.016 |
0.531 |
|
| 2015 |
Xiang J, Hurchla MA, Fontana F, Su X, Amend SR, Esser AK, Douglas GJ, Mudalagiriyappa C, Luker KE, Pluard T, Ademuyiwa FO, Romagnoli B, Tuffin G, Chevalier E, Luker GD, ... ... Weilbaecher KN, et al. CXCR4 Protein Epitope Mimetic Antagonist, POL5551, Disrupts Metastasis and Enhances Chemotherapy Effect in Triple Negative Breast Cancer. Molecular Cancer Therapeutics. PMID 26269605 DOI: 10.1158/1535-7163.MCT-15-0252 |
0.428 |
|
| 2015 |
Ellison TS, Atkinson SJ, Steri V, Kirkup BM, Preedy ME, Johnson RT, Ruhrberg C, Edwards DR, Schneider JG, Weilbaecher K, Robinson SD. Suppression of β3-integrin in mice triggers a neuropilin-1-dependent change in focal adhesion remodelling that can be targeted to block pathological angiogenesis. Disease Models & Mechanisms. 8: 1105-19. PMID 26159543 DOI: 10.1242/Dmm.019927 |
0.316 |
|
| 2015 |
Junankar S, Shay G, Jurczyluk J, Ali N, Down J, Pocock N, Parker A, Nguyen A, Sun S, Kashemirov B, McKenna CE, Croucher PI, Swarbrick A, Weilbaecher K, Phan TG, et al. Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer. Cancer Discovery. 5: 35-42. PMID 25312016 DOI: 10.1158/2159-8290.Cd-14-0621 |
0.524 |
|
| 2015 |
Amend SR, Uluckan O, Hurchla M, Leib D, Novack DV, Silva M, Frazier W, Weilbaecher KN. Thrombospondin-1 regulates bone homeostasis through effects on bone matrix integrity and nitric oxide signaling in osteoclasts. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 30: 106-15. PMID 25042340 DOI: 10.1002/Jbmr.2308 |
0.778 |
|
| 2014 |
Steri V, Ellison TS, Gontarczyk AM, Weilbaecher K, Schneider JG, Edwards D, Fruttiger M, Hodivala-Dilke KM, Robinson SD. Acute depletion of endothelial β3-integrin transiently inhibits tumor growth and angiogenesis in mice. Circulation Research. 114: 79-91. PMID 24103390 DOI: 10.1161/Circresaha.114.301591 |
0.4 |
|
| 2013 |
Yang C, Davis JL, Zeng R, Vora P, Su X, Collins LI, Vangveravong S, Mach RH, Piwnica-Worms D, Weilbaecher KN, Faccio R, Novack DV. Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation. Cancer Discovery. 3: 212-23. PMID 23269702 DOI: 10.1158/2159-8290.Cd-12-0271 |
0.497 |
|
| 2013 |
Lansdell TA, Hurchla MA, Xiang J, Hovde S, Weilbaecher KN, Henry RW, Tepe JJ. Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo. Acs Chemical Biology. 8: 578-87. PMID 23198928 DOI: 10.1021/Cb300568R |
0.336 |
|
| 2013 |
Aft R, Weilbaecher K, Trinkaus K, Watson M, Bernadt C, Crouch E, Dahiya N, Ellis M, Ma C. Abstract OT2-6-12: A randomized pacebo-controlled phase II trial evaluating the effect of hedgehog inhibitor LDE225 on bone marrow disseminated tumor cells in women with early stage estrogen receptor negative and HER2 negative breast cancer Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Ot2-6-12 |
0.406 |
|
| 2012 |
Hurchla MA, Weilbaecher KN. Hedgehog-targeted therapeutics uncouple the vicious cycle of bone metastasis. Oncoimmunology. 1: 1411-1413. PMID 23243611 DOI: 10.4161/onci.21060 |
0.391 |
|
| 2012 |
Su X, Floyd DH, Hughes A, Xiang J, Schneider JG, Uluckan O, Heller E, Deng H, Zou W, Craft CS, Wu K, Hirbe AC, Grabowska D, Eagleton MC, Townsley S, ... ... Weilbaecher KN, et al. The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling. The Journal of Clinical Investigation. 122: 3579-92. PMID 22996695 DOI: 10.1172/Jci38576 |
0.798 |
|
| 2012 |
Heller E, Hurchla MA, Xiang J, Su X, Chen S, Schneider J, Joeng KS, Vidal M, Goldberg L, Deng H, Hornick MC, Prior JL, Piwnica-Worms D, Long F, Cagan R, ... Weilbaecher KN, et al. Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. Cancer Research. 72: 897-907. PMID 22186138 DOI: 10.1158/0008-5472.Can-11-2681 |
0.442 |
|
| 2012 |
Zheleznyak A, Wadas TJ, Sherman CD, Wilson JM, Kostenuik PJ, Weilbaecher KN, Anderson CJ. Integrin α(v)β₃ as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 14: 500-8. PMID 21853370 DOI: 10.1007/S11307-011-0512-4 |
0.328 |
|
| 2012 |
Blumer KJ, Weilbaecher K, Piwnica-Worms D. Bioluminescence imaging of prenylation inhibition - Response Clinical Cancer Research. 18: 6078. DOI: 10.1158/1078-0432.Ccr-12-2737 |
0.363 |
|
| 2012 |
Zhang K, Kim S, Cremasco V, Hirbe AC, Collins L, Piwnica-Worms D, Novack DV, Weilbaecher K, Faccio R. Correction: CD8 + T cells regulate bone tumor burden independent of osteoclast resorption Cancer Research. 72. DOI: 10.1158/0008-5472.Can-11-3840 |
0.679 |
|
| 2011 |
Zhang K, Kim S, Cremasco V, Hirbe AC, Collins L, Piwnica-Worms D, Novack DV, Weilbaecher K, Faccio R. CD8+ T cells regulate bone tumor burden independent of osteoclast resorption. Cancer Research. 71: 4799-808. PMID 21602433 DOI: 10.1158/0008-5472.Can-10-3922 |
0.746 |
|
| 2011 |
Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nature Reviews. Cancer. 11: 411-25. PMID 21593787 DOI: 10.1038/Nrc3055 |
0.459 |
|
| 2011 |
Schneider JG, Amend SR, Weilbaecher KN. Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. Bone. 48: 54-65. PMID 20850578 DOI: 10.1016/j.bone.2010.09.016 |
0.423 |
|
| 2011 |
Shay G, Hornick M, Heys S, Weilbaecher K, Rogers M. Abstract LB-159: Bisphosphonates are internalised by myeloid derived suppressor cells (MDSCs) in vivo in a mouse model of breast cancer Immunology. 71. DOI: 10.1158/1538-7445.Am2011-Lb-159 |
0.352 |
|
| 2010 |
Rauch DA, Hurchla MA, Harding JC, Deng H, Shea LK, Eagleton MC, Niewiesk S, Lairmore MD, Piwnica-Worms D, Rosol TJ, Weber JD, Ratner L, Weilbaecher KN. The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice. Plos One. 5: e15755. PMID 21209895 DOI: 10.1371/Journal.Pone.0015755 |
0.532 |
|
| 2010 |
Vidal M, Salavaggione L, Ylagan L, Wilkins M, Watson M, Weilbaecher K, Cagan R. A role for the epithelial microenvironment at tumor boundaries: evidence from Drosophila and human squamous cell carcinomas. The American Journal of Pathology. 176: 3007-14. PMID 20363916 DOI: 10.2353/Ajpath.2010.090253 |
0.349 |
|
| 2010 |
Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, ... ... Weilbaecher K, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. The Lancet. Oncology. 11: 421-8. PMID 20362507 DOI: 10.1016/S1470-2045(10)70054-1 |
0.418 |
|
| 2010 |
Hirbe AC, Morgan EA, Weilbaecher KN. The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases? Current Pharmaceutical Design. 16: 1284-90. PMID 20166978 DOI: 10.2174/138161210791034012 |
0.747 |
|
| 2010 |
Lin Y, Lin S, Watson M, Trinkaus KM, Kuo S, Naughton MJ, Weilbaecher K, Fleming TP, Aft RL. A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy. Breast Cancer Research and Treatment. 123: 691-9. PMID 19967557 DOI: 10.1007/S10549-009-0664-Y |
0.363 |
|
| 2010 |
Morgan EA, Schneider JG, Baroni TE, Uluçkan O, Heller E, Hurchla MA, Deng H, Floyd D, Berdy A, Prior JL, Piwnica-Worms D, Teitelbaum SL, Ross FP, Weilbaecher KN. Dissection of platelet and myeloid cell defects by conditional targeting of the beta3-integrin subunit. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 24: 1117-27. PMID 19933310 DOI: 10.1096/Fj.09-138420 |
0.364 |
|
| 2010 |
Aft R, Naughton M, Trinkaus K, Weilbaecher K. Abstract P6-14-04: Effect of Zoledronic Acid on Disease-Free Survival and Overall Survival in Women with Clinic Stage II/III Undergoing Neoadjuvant Chemotherapy for Breast Cancer Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P6-14-04 |
0.341 |
|
| 2010 |
Roop R, Naughton M, Schneider J, Lammers P, Pluard T, Johnson F, Eby C, Weilbaecher K. Abstract P3-02-12: Effect of Platelet Function Inhibition on Circulating Tumor Cells in Patients with Metastatic Breast Cancer: A Randomized Phase II Trial Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P3-02-12 |
0.396 |
|
| 2009 |
Wadas TJ, Deng H, Sprague JE, Zheleznyak A, Weilbaecher KN, Anderson CJ. Targeting the alphavbeta3 integrin for small-animal PET/CT of osteolytic bone metastases. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 50: 1873-80. PMID 19875645 DOI: 10.2967/Jnumed.109.067140 |
0.414 |
|
| 2009 |
Hirbe AC, Roelofs AJ, Floyd DH, Deng H, Becker SN, Lanigan LG, Apicelli AJ, Xu Z, Prior JL, Eagleton MC, Piwnica-Worms D, Rogers MJ, Weilbaecher K. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone. 44: 908-16. PMID 19442620 DOI: 10.1016/J.Bone.2009.01.010 |
0.761 |
|
| 2009 |
Uluçkan O, Becker SN, Deng H, Zou W, Prior JL, Piwnica-Worms D, Frazier WA, Weilbaecher KN. CD47 regulates bone mass and tumor metastasis to bone. Cancer Research. 69: 3196-204. PMID 19276363 DOI: 10.1158/0008-5472.Can-08-3358 |
0.773 |
|
| 2009 |
Xu Z, Hurchla MA, Deng H, Uluçkan O, Bu F, Berdy A, Eagleton MC, Heller EA, Floyd DH, Dirksen WP, Shu S, Tanaka Y, Fernandez SA, Rosol TJ, Weilbaecher KN. Interferon-gamma targets cancer cells and osteoclasts to prevent tumor-associated bone loss and bone metastases. The Journal of Biological Chemistry. 284: 4658-66. PMID 19059914 DOI: 10.1074/Jbc.M804812200 |
0.457 |
|
| 2009 |
Chavez-MacGregor M, Weilbaecher K, Aft R. Bone Marrow Micrometastases: Is there a Role for Bisphosphonates? Breast Diseases: a Year Book Quarterly. 19: 302-304. DOI: 10.1016/S1043-321X(09)79233-1 |
0.531 |
|
| 2008 |
Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, Body JJ, Boyce BF, Calvi LM, Hadji P, McCloskey EV, Saad F, Smith MR, Suva LJ, Taichman RS, Vessella RL, ... Weilbaecher KN, et al. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 6387-95. PMID 18927277 DOI: 10.1158/1078-0432.Ccr-08-1572 |
0.474 |
|
| 2008 |
Vaira S, Johnson T, Hirbe AC, Alhawagri M, Anwisye I, Sammut B, O'Neal J, Zou W, Weilbaecher KN, Faccio R, Novack DV. RelB is the NF-kappaB subunit downstream of NIK responsible for osteoclast differentiation. Proceedings of the National Academy of Sciences of the United States of America. 105: 3897-902. PMID 18322009 DOI: 10.1073/Pnas.0708576105 |
0.676 |
|
| 2008 |
Uluçkan O, Eagleton MC, Floyd DH, Morgan EA, Hirbe AC, Kramer M, Dowland N, Prior JL, Piwnica-Worms D, Jeong SS, Chen R, Weilbaecher K. APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice. Journal of Cellular Biochemistry. 104: 1311-23. PMID 18260128 DOI: 10.1002/Jcb.21709 |
0.796 |
|
| 2008 |
Apicelli AJ, Maggi LB, Hirbe AC, Miceli AP, Olanich ME, Schulte-Winkeler CL, Saporita AJ, Kuchenreuther M, Sanchez J, Weilbaecher K, Weber JD. A non-tumor suppressor role for basal p19ARF in maintaining nucleolar structure and function. Molecular and Cellular Biology. 28: 1068-80. PMID 18070929 DOI: 10.1128/Mcb.00484-07 |
0.627 |
|
| 2008 |
Wildes TM, Procknow E, Weilbaecher K, Vij R. Effect of dasatinib on bone metabolism in multiple myeloma Journal of Clinical Oncology. 26: 8568-8568. DOI: 10.1200/Jco.2008.26.15_Suppl.8568 |
0.428 |
|
| 2008 |
Aft R, Watson M, Ylagan L, Chavez-MacGregor M, Trinkaus K, Zhai J, Naughton M, Weilbaecher K. Effect of zoledronic acid on bone marrow micrometastases in women undergoing neoadjuvant chemotherapy for breast cancer Journal of Clinical Oncology. 26: 1021-1021. DOI: 10.1200/Jco.2008.26.15_Suppl.1021 |
0.468 |
|
| 2008 |
Floyd D, Wu K, Hirbe A, Uluckan O, Eagleton M, Conley P, Weilbaecher K. P7. The ADP receptor P2Y12 is expressed in developing osteoclasts and is required for full osteoclast function and tumor associated osteolysis Cancer Treatment Reviews. 34: 15. DOI: 10.1016/J.Ctrv.2008.03.048 |
0.757 |
|
| 2007 |
Watson MA, Ylagan LR, Trinkaus KM, Gillanders WE, Naughton MJ, Weilbaecher KN, Fleming TP, Aft RL. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5001-9. PMID 17785550 DOI: 10.1158/1078-0432.CCR-07-0024 |
0.418 |
|
| 2007 |
Hirbe AC, Rubin J, Uluçkan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Weilbaecher KN. Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone. Proceedings of the National Academy of Sciences of the United States of America. 104: 14062-7. PMID 17715292 DOI: 10.1073/Pnas.0705203104 |
0.819 |
|
| 2007 |
Sprague JE, Kitaura H, Zou W, Ye Y, Achilefu S, Weilbaecher KN, Teitelbaum SL, Anderson CJ. Noninvasive imaging of osteoclasts in parathyroid hormone-induced osteolysis using a 64Cu-labeled RGD peptide. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 48: 311-8. PMID 17268030 |
0.389 |
|
| 2007 |
Hirbe AC, Uluçkan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Trinkaus K, Apicelli A, Weilbaecher K. Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner. Blood. 109: 3424-31. PMID 17192391 DOI: 10.1182/Blood-2006-09-048686 |
0.809 |
|
| 2006 |
Hirbe A, Morgan EA, Uluçkan O, Weilbaecher K. Skeletal complications of breast cancer therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 6309s-6314s. PMID 17062720 DOI: 10.1158/1078-0432.Ccr-06-0652 |
0.749 |
|
| 2006 |
Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, Cleeland CS, Clohisy DR, Coleman RE, Cook RJ, Guise TA, Pearse RN, Powles TJ, Rogers MJ, Roodman GD, ... ... Weilbaecher KN, et al. Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 6209s-6212s. PMID 17062702 DOI: 10.1158/1078-0432.Ccr-06-1213 |
0.467 |
|
| 2006 |
Perez EA, Weilbaecher K. Aromatase inhibitors and bone loss. Oncology (Williston Park, N.Y.). 20: 1029-39; discussion . PMID 16986348 |
0.418 |
|
| 2006 |
Aft R, Naughton M, Trinkuas K, Watson M, Weilbaecher K. Reversal of adverse effects of neoadjuvant chemotherapy on bone turnover in pre- and post-menopausal women with zoledronic acid Journal of Clinical Oncology. 24: 556-556. DOI: 10.1200/Jco.2006.24.18_Suppl.556 |
0.499 |
|
| 2005 |
Gauvain KM, Garbow JR, Song SK, Hirbe AC, Weilbaecher K. MRI detection of early bone metastases in B16 mouse melanoma models Clinical and Experimental Metastasis. 22: 403-411. PMID 16283483 DOI: 10.1007/S10585-005-1264-9 |
0.74 |
|
| 2005 |
Gao L, Deng H, Zhao H, Hirbe A, Harding J, Ratner L, Weilbaecher K. HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood. 106: 4294-302. PMID 16118323 DOI: 10.1182/Blood-2005-04-1730 |
0.764 |
|
| 2004 |
Aft R, Ylagan L, Sadeghi S, Eberlein T, Herrmann V, Dietz J, Fracasso P, Naughton M, Weilbaecher K. Effect of neoadjuvant chemotherapy on bone marrow micrometastases in women with locally advanced breast cance. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 697. PMID 28017028 DOI: 10.1200/Jco.2004.22.14_Suppl.697 |
0.498 |
|
| 2003 |
Bakewell SJ, Nestor P, Prasad S, Tomasson MH, Dowland N, Mehrotra M, Scarborough R, Kanter J, Abe K, Phillips D, Weilbaecher KN. Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proceedings of the National Academy of Sciences of the United States of America. 100: 14205-10. PMID 14612570 DOI: 10.1073/Pnas.2234372100 |
0.524 |
|
| 1990 |
Namikawa R, Weilbaecher KN, Kaneshima H, Yee EJ, McCune JM. Long-term human hematopoiesis in the SCID-hu mouse. The Journal of Experimental Medicine. 172: 1055-63. PMID 2212942 DOI: 10.1084/Jem.172.4.1055 |
0.343 |
|
| Show low-probability matches. |